JUNS
Jupiter Neurosciences, Inc.·Healthcare
0.24
3.478%(+0.01)
Market OpenLast Updated: — ET
52W L: $0.1752W H: $3.33
JUNS NEWS
globenewswire.com
11h ago
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
Investigational Oral Candidate JOTROL ™ Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available
accessnewswire.com
1d ago
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering").
globenewswire.com
6d ago
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Cash Runway Extended to Finance the Parkinson's Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced the closing of its registered direct offering, pursuant to the securities purchase agreements with certain investors, for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering. The gross proceeds of the offering were approximately $2.0 million (the "Offering").
globenewswire.com
May 20
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 7,142,858 shares of common stock in a registered direct offering.
benzinga.com
May 20
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) shares are trading higher Wednesday after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.
globenewswire.com
May 20
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002 to Jupiter Neurosciences in a Transaction Valued at Over $100 Million USD
